|Company name||Nabriva Therapeutics plc|
|Class period||November 1, 2018 – April 30, 2019|
|Court||Southern District of New York|
NEW YORK, July 3, 2019 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Nabriva Therapeutics plc (NASDAQ: NBRV) securities between November 1, 2018 and April 30, 2019 (the “Class Period”). Investors have until July 8, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that throughout the class period made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the complaint alleges that defendants failed to disclose to investors that: (1) the company’s manufacturers failed to meet good manufacturing practices; (2) these manufacturers would be subject to inspections by the FDA in connection with the company’s NDA; (3) as a result of the manufacturing deficiencies, the company’s NDA for CONTEPO was unlikely to be approved by the FDA; and (4) as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
If you purchased Nabriva securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.